NeoGenomics Inc., a prominent leader in oncology testing services, has announced the appointment of Felicia Williams to its Board of Directors. The move marks an exciting new chapter for the company as it continues to strengthen its leadership team. Effective from November 1, 2024, Felicia Williams will join the board as an independent director, bringing with her over three decades of invaluable experience across multiple industries.
Known for her outstanding career in finance and leadership, Williams’ extensive background spans critical areas such as treasury, risk management, accounting, and audit. Her leadership roles at some of the world’s biggest companies, including Macy’s Inc., The Coca-Cola Company, and Bristol Myers-Squibb, have earned her a reputation as a seasoned business strategist with a sharp understanding of global operations.
In addition to her role at NeoGenomics, Felicia Williams currently sits on the boards of Paycom and Anywhere Real Estate, where her financial expertise and corporate governance knowledge are highly valued. Her wealth of experience and diverse skill set will undoubtedly complement NeoGenomics’ already impressive Board, which is known for its world-class talent and unique range of expertise.
As part of her new role at NeoGenomics, Williams will be involved in two key board committees: the Audit and Finance Committee and the Nominating and Corporate Governance Committee. These responsibilities reflect her deep knowledge in corporate finance, risk management, and governance—critical areas that align with the company’s ongoing efforts to maintain strong financial health and strategic direction.
Commenting on the appointment, Lynn Tetrault, Chairwoman of the Board at NeoGenomics, said: “We are fortunate to welcome Felicia Williams to our board of directors, bringing her experience across the spectrum of finance, accounting, audit, and enterprise risk management to NeoGenomics. We look forward to working together to support the company and improve patient care.”
With Felicia Williams now on board, NeoGenomics adds yet another highly qualified leader to its team, enhancing its ability to navigate the complexities of the oncology sector. Her appointment comes at a time when NeoGenomics is focused on expanding its reach and continuing to provide cutting-edge diagnostic services that improve the lives of cancer patients worldwide.
Having led significant corporate transformations and financial strategies in her previous roles, Williams’ appointment brings a wealth of knowledge that is expected to strengthen NeoGenomics’ governance framework and support its long-term growth strategy. The company’s continued commitment to patient care, combined with the strategic guidance of its newly diversified board, ensures that NeoGenomics will remain at the forefront of the healthcare industry.
Felicia Williams’ career trajectory stands as a testament to her deep understanding of the global business landscape, and her expertise will no doubt play a crucial role in supporting NeoGenomics as it strives to meet the ever-evolving needs of its patients and stakeholders.
In welcoming Williams to the team, NeoGenomics is positioning itself for continued success, with a board made up of leaders who bring a wealth of skills and knowledge to the table. As the company continues to drive innovation and make a significant impact in oncology testing, the addition of such an experienced director strengthens its foundation and commitment to excellence in the years to come.